AbbVie reports 74% response rate for Etentamig in pivotal trial
AbbVie said Etentamig delivered a 74% overall response rate in a pivotal blood-cancer trial, while standard treatments managed 45.7%. Shares were priced at $260.445.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.